The technology offers a no-implant interatrial shunt therapy for patients suffering from heart failure with preserved (HFpEF) and mid-range ejection fraction (HFmrEF) who remain symptomatic despite optimal guideline directed medical therapy. Read More →
Congestive heart failure treatment developer Alleviant Medical filed an SEC Form D to confirm the sale of $6.5 million in an equity offering. The Austin, Texas-based company reached its total offering amount of $6.5 million after making the first sale in the new notice on May 1. It had no intention of letting the offering last longer than one year and did not make it in connection with a business transaction. Read More →
The Texas Medical Center, the largest medical complex in the world, today announced the TMC Venture Fund, a $25 million initiative designed to support technologies and early-stage companies to flourish in Houston’s health care ecosystem and further the TMC’s mission to advance health, education and research.